You are here:

rasagiline 1mg (Azilect)


Following a resubmission.

Rasagiline (Azilect) is not recommended within NHS Scotland for the treatment of idiopathic Parkinson’s disease as adjunct therapy (with levodopa) in patients with end of dose fluctuations.

Rasagiline reduces off-time in patients with Parkinson’s disease and end of dose fluctuations on levodopa, similar to reductions shown with the less effective of two currently marketed catechol-O-methyl transferase inhibitors. The economic case has not been demonstrated.

Drug Details

Drug Name: rasagiline 1mg (Azilect)
SMC Drug ID: 255/06
Manufacturer: Lundbeck Ltd
Indication: Treatment of ideopathic Parkinson’s Disease
BNF Category:
Sub Category: 4.9 Drugs used in Parkinsonism and related disorders
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 11 December 2006

Archived Advice

Full submission 13 March 2006